Table 4. Univariate analysis of PFS and OS for all LAC patients.

	PFS			OS
	95%CI	HR	P value	95%CI	HR	P value
Age(≥58,<58)	0.752-1.502	1.063	0.730	0.804-1.605	1.136	0.470
Sex(female, male)	0.517-1.031	0.730	0.074	0.510-1.018	0.726	0.054
Smoking status(yes, no)	0.568-1.150	0.808	0.237	0.612-1.238	0.870	0.440
Tumour location(left, right)	0.584-1.169	0.827	0.281	0.596-1.193	0.843	0.335
Lesion type(central, peripheral)	1.091-2.182	1.543	0.014	1.086-2.171	1.536	0.015
pTNM status(I+II,III+IV)	2.822-6.063	4.136	<0.001	2.950-6.317	4.137	<0.001
EGFR mutation status(yes, no)	0.813-1.650	1.158	0.416	0.785-1.590	1.117	0.539
Serum CEA(≤5 ng/mL, >5 ng/mL)	1.383-2.776	1.959	<0.001	1.315-2.639	1.863	<0.001
E-cadherin(negative, positive)	0.457-0.952	0.660	0.026	0.460-0.958	0.664	0.028
Cripto-1(low, high)	1.734-3.688	2.529	<0.001	1.742-3.700	2.539	<0.001

PFS progression-free survival, OS overall survival, CI confidential interval, HR hazard ratio.